Cancer patients who undergo surgery or radiation can develop persistent focal pain at the site of radiation or surgery. Twelve patients who had surgery or radiation for local cancer and failed at least two analgesic medications for pain control were prospectively enrolled in a research protocol.
Introduction
Surgery and radiation for cancer treatment has focal side effects on skin, soft tissues, muscles and nerves leading to muscle atrophy, fibrosis and contracture [1] [2] [3] . Approximately 30% of the patients with head and neck cancer and 20%-60% of the patients with breast cancer will have chronic pain localized to the site of radiation or surgery [4, 5] . Treatment of post-surgical/post-radiation pain is difficult and failures are not uncommon. Moderate to severe postsurgical pain often requires opioids, which have abuse potential and in this context often fail pain management [6] . Local treatment for persistent pain with lidocaine patches and hyaluronic acid has provided only temporary relief [7, 8] .
Botulinum neurotoxins (BoNTs) block the release of neurotransmitters from presynaptic vesicles via inhibition of SNARE proteins, i.e. Soluble NSF (N-ethylmaleimide-sensitive factor) Attachment protein Receptor, which promote rupture of these vesicles [9] . The underlying mechanism of action of BoNTs in pain relief has not been yet elucidated convincingly. The animal data suggests blocking the release of number of pain modulators from presynaptic vesicles in addition to acetylcholine. Blinded clinical trials in humans indicate efficacy or probable efficacy in management of several pain disorders [10] . Pain relief after local injection of onabotulinum toxin A (OnaA) and abobotulinum toxin A (AboA) has been reported before in a small number of patients with post-radiation/post-surgical pain (Table 1) but not with incobotulinum toxin A (IncoA). In this communication, we report the results of a pilot, prospective study, which assessed the efficacy and safety of incobotulinum toxin A in focal cancer pain of 8 subjects after cancer surgery or radiation.
Methods

Participants
Adult subjects with cancer and focal chronic pain after surgery and/or radiation who have failed to respond to at least two analgesic medications were eligible to participate in the study. Participants were excluded if they had received prior botulinum toxin treatment, had diseases of neuromuscular junction or were on antibiotics or pharmaceutical agents with potential to affect neuromuscular transmission.
Study Design
The study was approved by the Yale Human Use Committee and registered at ClinicalTrials.gov (NCT01931865). Subjects were enrolled in the study after meeting the eligibility criteria and signing an informed consent. Demographic data, history, type of cancer, location of pain and type of medications were recorded along a neurological examination during the first visit ( Table 2 ). The level of pain was measured by the visual analog scale (VAS 0-10) and improvement of the quality of life (QOL) was assessed by the American Chronic Pain Association questionnaire. The patients' level of satisfaction with treatment was measured by Patients' Global Impression of Change (PGIC) at the subsequent visits. Neurologist with over 20 years' experience in botulinum toxin treatment (B.J.) performed the incobotulinum toxin A injections. When pain was in the form of muscle spasm, incobotulinum toxin A was injected intramuscularly. In case of neuropathic, superficial pain with typical burning quality the injections were subcutaneous and in a grid like pattern. The location and type of pain, pattern of injections and dose per patient is depicted in Table 2 . The VAS and QOL were reassessed at baseline and at 4, 6, 8, and 12 weeks. Patients' Global Impression of Change (PGIC) was also recorded at 4, 6, 8 and 12 weeks. The neurological examination was repeated at 6 weeks and 12 weeks. Patients' medications during the study remained unchanged unless recommended by the treating oncologist.
Primary and Secondary Outcomes
The primary outcome in this study was improvement in pain as defined by 2 or more grade change in the VAS at 6 weeks after injection. The secondary outcomes were changes in the PGIC and QOL. The side effects were obtained and documented during each assessment. 
Results
A total of 25 patients were screened and 12 were enrolled in the study. Four patients did not finish the study. Two died because of advanced cancer, one could not return for follow up due to poor general health and one also did not return due to a skin reaction which developed shortly after incobotulinum toxin A injection. Of the remaining 8 who completed the study, four were female. The mean age was 55 years (range, 31-70 years). Patient's demographic information is presented in Table 2 . Incobotulinum toxin A was diluted with saline (1 cc per 100 units) and injected via a 27.5 gauge needle intramuscularly, subcutaneously (SC) or both depending on the nature of pain (SC for neuropathic pain with allodynia). The total dose per patient varied from 80-100 units. Table 2 provides information regarding the site of injections and dose of injected toxin per each muscle.
All patients demonstrated significant improvement in VAS (more than two grade improvement) at 6 weeks ( Table 2) . Five of 8 patients retained the same degree of improvement at 12 weeks. At 6 and 12 weeks, all patients reported their pain as improved with 7 of 8 reporting the pain as much improved or very much improved ( Table 2 ). The quality of life (American Chronic Pain Association) improved in 3 of 8 patients (38%). The skin rash, which developed in that one patient, was maculo-papillary in nature and affected the upper torso on her back from T1 to T7 level bilaterally (not at the site of injection). It developed within few days after injection and gradually disappeared over 4 weeks. The cause and effect could not be clearly established. Other patients did not demonstrate any side effects after injections.
Discussion
Local post-surgical chronic pain occurs in 20%-70% of cancer patients [15] . The cause of chronic and maintained pain is believed to be due to peripheral receptor sensitization at the site of injury and central neuronal sensitization at spinal or supra-spinal levels. The peripheral noxious stimulus leads to local accumulation of the pain modulators (calcitonin gene related peptide, substance P, glutamate), which cause vasodilation and local inflammation. The inflammation leads to a series of complex reactions such as proliferation of CNS macrophages and impaired receptors inhibitory function. The nerve damage also increases sodium release and causes ectopic nerve discharge as a result of neuroma formation at the site of injury. These phenomena lead to sensitization of peripheral nerve endings and central sensitizations [16] [17] [18] .
Radiation therapy has acute and delayed side effects the magnitude of which is dose dependent. Animal studies have shown focal loss of capillaries and muscle degeneration 2-4 months after a one-time 2000 rad (20 Gy) treatment. The damage increases collagen and decreases proteoglycans in extracellular matrix leading to disorganized structure and fibrotic tissue formation [11] . Focal pain is reported in about 20%-30% of patients after radiation therapy of head and neck cancer [12, 19] .
Data from animal studies have proposed a variety of mechanisms to explain the botulinum toxin (BoNT) induced analgesia after local injection. The data suggests that both peripheral and central mechanisms play a role in BoNT induced analgesia, although the exact mechanisms still not clear. Animal data demonstrates inhibition of substance P and calcitonin gene related peptide (CGRP) release from dorsal root ganglia (DRG) after peripheral injection [20, 21] and modulation of sodium channels in peripheral and central nervous system [22] . An anti-inflammatory effect is strongly suggested for both OnaA and RimaB botulinum toxins in the formalin model of pain. Toxin injection into the paw of rat or mice 7-10 days before formalin injection significantly reduces the peak of inflammatory pain and local accumulation of glutamate in the injected area [23, 24] . A central effect upon spinal neurons through retrograde transfer and transcytosis has been proposed by a number of investigators [25, 26] including action via enhancement of Gabaergic mechanisms [27] . Blinded clinical trials have shown efficacy in some areas of human pain such as low back pain [28] , plantar fasciitis [29] , posttraumatic/post herpetic neuralgia [30] and migraine [31] . This is the first report on the efficacy and safety of incobotulinum toxin A in cancer patients with post-surgical and post-radiation pain. In this prospective study, all patients met the primary outcome i.e., improvement of pain by two or more grades as assessed by VAS. Seven of the eight patients also reported significant satisfaction with treatment (secondary outcome-PGIC). The rather low number of patients (3 out of 8) who showed improvement of QOL in this study is in contrast with VAS and PGIC results. This is most likely due to the complexity of the quality of life questionnaire and to the fact that in patients with advanced cancer, many factors other than pain influence the quality of life. Considering the high incidence of placebo response in subjects with pain, the value of VAS in this population need to be evaluated in a blinded study. Incobotulinum toxin A treatment improved both muscle spasms and neuropathic pain (burning and jabbing pain). This finding is in agreement with the prior reports on the efficacy of other botulinum toxin as in management of this type of human pain ( Table 1) . Prior studies also reported no significant side effects with similar applied doses.
In conclusion, the result of our study and other open studies suggests the efficacy and safety of all three types of BoNT-A in alleviating the chronic pain in cancer patients after surgery or radiation. The limitation of these studies is the small number of the studied subjects and the open design of these studies. Blinded, placebo-controlled studies are necessary to support or refute the efficacy of botulinum toxin injections in relieving post-surgical or post-radiation pain in cancer patients.
